Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC

INTRODUCTION: Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without radiation therapy (RT) in patients with advanced NSCLC. METHODS: Patients with progressive disease after anti–program...

Descripción completa

Detalles Bibliográficos
Autores principales: Negrao, Marcelo V., Papadimitrakopoulou, Vassiliki A., Price, Andrew C., Tam, Alda L., Furqan, Muhammad, Laroia, Sandeep T., Massarelli, Erminia, Pacheco, Jose, Heymach, John V., Tsao, Anne S., Walker, Gary V., Vora, Lalit, Mauro, David, Kelley, Heather, Wooldridge, James E., Krieg, Arthur M., Niu, Jiaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011508/
https://www.ncbi.nlm.nih.gov/pubmed/36925644
http://dx.doi.org/10.1016/j.jtocrr.2022.100423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011508/
https://www.ncbi.nlm.nih.gov/pubmed/36925644
http://dx.doi.org/10.1016/j.jtocrr.2022.100423

Ejemplares similares